Belarusian-Dutch joint venture Pharmland was established in 1998, initially located in the leased areas of OAO Nesvizh Plant of Medical Preparations. The starting line was the production of infusion solutions in containers of PVC with an estimated volume of 330,000 packages per month. For the first time on the territory of the CIS, an infusion solution of isotonic sodium chloride, packed in a PVC container, came off the assembly line of the young enterprise Pharmland. This type of packaging has won recognition of medical institutions of the Republic of Belarus.
Pharmland specialists in cooperation with specialists of the Belarusian State University with the direct participation of the leading manufacturers of immunoenzyme diagnostic test systems and reagents of the Russian Federation have developed immunoenzymatic reagent kits. In the same year, their production was mastered.
September 9, 2009, the opening of the own premises of the plant Pharmland for the production of liquid medicines (solutions for injection and infusion, concentrates for hemodialysis) was held. About 10 million US dollars were invested in production, including more than 4.5 million US dollars in the most advanced equipment.
A new workshop for the production of solid dosage forms (tablets, capsules, powders) has been built and put into operation. The development of new production was the result of international cooperation of pharmaceutical companies - Holden Medical Laboratories Pvt. Ltd. (India), Holden Medical B.V. (Netherlands) and JV Pharmland LLC. Until now, companies are jointly implementing pharmaceutical development, the search for and selection of high-quality pharmaceutical substances and auxiliary ingredients, and the production of ready-made dosage forms.
As a result of cooperation with the company Imres B.V. (Netherlands), the industrial production of biologically active food supplements has been mastered.
The development of the composition and technologies has been completed and the manufacture of enteral nutrition mixtures has been started: Enterolin Optimum, Enterolin high-protein and high-calorie, Enterolin with dietary fiber, Enterolin high-protein and high-calorie with dietary fiber.
Parmland has certificates of national GMP for the areas of infusion and injection production, tableted, encapsulated medicinal products, syrups, a certificate of compliance of quality management with the requirements of ISO 9001 for the production site of medical devices.
The first domestic expendable materials for conducting plasmapheresis and thrombocytopheresis have been developed. A new investment facility was put into operation - a plant for the production of medicines based on blood plasma. The volume of investment investments amounted to 23 million US dollars.
Production capacity of the plant will allow to process 650 thousand liters of plasma per year. The enterprise Parmland plans to master the production of albumin, immunoglobulins, coagulation factors VIII and IX.
The enterprise registered and introduced into production new forms of medicines: sprays Oroseptin (INN-Phenol) and Miramistin.
The manufacture of Sophir (INN - Sofosbuvir) medicinal product, 400 mg in tablets, is one of the most effective means in complex therapy of hepatitis C.